📊 TGTX Key Takeaways
Is Tg Therapeutics, Inc.. (TGTX) a Good Investment?
TG Therapeutics demonstrates impressive revenue growth of 87.3% YoY with respectable 17% operating margins, but this is severely undermined by negative operating cash flow of -$17.9M despite positive net income, coupled with a high debt-to-equity ratio of 1.28x. The disconnect between reported profitability and actual cash generation signals fundamental operational challenges or earnings quality concerns that cannot be overlooked.
Why Buy Tg Therapeutics, Inc.. Stock? TGTX Key Strengths
- Strong top-line growth of 87.3% YoY demonstrating significant revenue momentum and market acceptance
- Solid operating margin of 17% and net margin of 9.7% indicating competitive positioning and pricing power
- Excellent liquidity with current ratio of 5.81x and $442.2M cash balance providing near-term runway
- Strong interest coverage of 15.2x enabling comfortable debt service without financial distress risk
TGTX Stock Risks: Tg Therapeutics, Inc.. Investment Risks
- Critical negative operating cash flow of -$17.9M despite $19.8M net income indicates severe working capital deterioration or earnings quality issues
- Negative free cash flow of -$17.9M is unsustainable and will erode the cash position if operational cash generation does not reverse immediately
- Elevated leverage with debt-to-equity of 1.28x and $745.1M debt amplifies financial risk if revenue growth slows or cash burn accelerates
- Exceptionally low capital returns (ROE 3.4%, ROA 1.3%) suggest inefficient asset utilization and poor capital deployment despite profitability
Key Metrics to Watch
- Operating cash flow reversal and root cause analysis of OCF/net income divergence in subsequent quarters
- Days sales outstanding (DSO) and accounts receivable trends to assess collection efficiency
- Debt maturity schedule and refinancing requirements given high leverage relative to cash generation
- Gross margin sustainability as revenue scales and competitive intensity increases
Tg Therapeutics, Inc.. (TGTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.81x current ratio provides a solid financial cushion.
TGTX Profit Margin, ROE & Profitability Analysis
TGTX vs Healthcare Sector: How Tg Therapeutics, Inc.. Compares
How Tg Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Tg Therapeutics, Inc.. Stock Overvalued? TGTX Valuation Analysis 2026
Based on fundamental analysis, Tg Therapeutics, Inc.. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Tg Therapeutics, Inc.. Balance Sheet: TGTX Debt, Cash & Liquidity
TGTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Tg Therapeutics, Inc..'s revenue has grown significantly by 164% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.09 reflects profitable operations.
TGTX Revenue Growth, EPS Growth & YoY Performance
TGTX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $120.9M | $5.1M | $0.03 |
| Q3 2025 | $83.9M | $52.0K | $0.00 |
| Q2 2025 | $73.5M | -$3.8M | $-0.03 |
| Q1 2025 | $63.5M | $5.1M | $0.03 |
| Q3 2024 | $83.9M | $52.0K | $0.00 |
| Q2 2024 | $16.1M | -$3.8M | $-0.03 |
| Q1 2024 | $7.8M | -$10.7M | N/A |
| Q3 2023 | $94.0K | $27.1M | $0.19 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Tg Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
TGTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Tg Therapeutics, Inc.. (CIK: 0001001316)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TGTX
What is the AI rating for TGTX?
Tg Therapeutics, Inc.. (TGTX) has an AI rating of SELL with 70% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TGTX's key strengths?
Claude: Strong top-line growth of 87.3% YoY demonstrating significant revenue momentum and market acceptance. Solid operating margin of 17% and net margin of 9.7% indicating competitive positioning and pricing power.
What are the risks of investing in TGTX?
Claude: Critical negative operating cash flow of -$17.9M despite $19.8M net income indicates severe working capital deterioration or earnings quality issues. Negative free cash flow of -$17.9M is unsustainable and will erode the cash position if operational cash generation does not reverse immediately.
What is TGTX's revenue and growth?
Tg Therapeutics, Inc.. reported revenue of $204.9M.
Does TGTX pay dividends?
Tg Therapeutics, Inc.. does not currently pay dividends.
Where can I find TGTX SEC filings?
Official SEC filings for Tg Therapeutics, Inc.. (CIK: 0001001316) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TGTX's EPS?
Tg Therapeutics, Inc.. has a diluted EPS of $0.12.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TGTX a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Tg Therapeutics, Inc.. has a SELL rating with 70% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TGTX stock overvalued or undervalued?
Valuation metrics for TGTX: ROE of 3.4% (sector avg: 15%), net margin of 9.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TGTX stock in 2026?
Our dual AI analysis gives Tg Therapeutics, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TGTX's free cash flow?
Tg Therapeutics, Inc..'s operating cash flow is $-17.9M, with capital expenditures of $51.0K. FCF margin is -8.8%.
How does TGTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 9.7% (avg: 12%), ROE 3.4% (avg: 15%), current ratio 5.81 (avg: 2).